ABOUT LSTCON
Life Science Tennessee presents LSTCON, an annual conference that brings together Tennessee‘s life science ecosystem to collaborate, learn, and build meaningful connections across the state.
Join us on November 19 for a daylong event for life science professionals, from startups to established companies from across the country. Programing includes state and national topics that affect life science companies daily. The day will conclude with a featured Venture Forum, where life science startups will pitch their prospective companies to the full conference audience for a chance to win $10,000!
The event will take place at the Westin Downtown in Nashville, Tennessee. If you would like to sponsor a session, suggest a speaker, or learn about other opportunities during the conference, please email us at [email protected].
Tickets
| LST Members | $225.00 |
| General | $350.00 |
| Academic Alliance Members
(Students/Academic Researchers/Post-Docs) |
$100.00 |
| TN Start Up | $100.00 |
ACCELERATING ACADEMIC RESEARCH FOR COMMERCIALIZATION
9:05 am | MAIN STAGE
Hear from two leading research universities about their strategies for transferring technology from the lab to the market. Sponsored by Patterson IP Law
KEYNOTE
9:45 am | MAIN STAGE
Hear from Tennessee Healthcare Hall of Fame inductee, renowned pharmacodynamics and pharmacogenomics researcher, and CEO of St. Jude Children’s Research Hospital (2004-14) William Evans about his career and the opportunity in Tennessee.
CMC CAPABILITIES IN TENNESSEE
10:00 am | MAIN STAGE
Developing an idea can be a daunting task. CDMO and service providers can bridge the gap between IP and a tangible product, not just in manufacturing. Learn how private life science companies across Tennessee accelerate research and provide entrepreneurs with the tools to develop their ideas to the clinical stage.
BREAKOUT: CLINICAL DEVELOPMENT 101 IN TENNESSEE
11:00 am | VANDERBILT II
As more than 80 percent of clinical studies in the U.S. fail to meet patient requirements, clinical trials can be a daunting task. Hear from leading researchers, CROs, and clinical trial experts talk about their experience building trials with pharmaceutical, medical device, and therapeutic companies, and how the industry can tackle systemic issues. This panel will cover the ‘101’ of everything your company needs to know and how to position your company’s clinical stage for success.
BREAKOUT: ALTERNATIVE FUNDING STRATEGIES
11:00 am | VANDERBILT I
We know life sciences is one of the most difficult industries to launch and scale a business. Access to significant capital is essential to technology development. Hear how one Tennessee startup successfully brokered a deal and how funders are approaching the industry.
LUNCH
12:00 pm
DRIVING GROWTH IN TENNESSEE’S LIFE SCIENCE INDUSTRY
12:15 pm
How do you bring innovation to the masses? From strategies to increase market penetration to ways to build connectivity to customers and other end users, successfully scaling a life science company is a feat. This fireside chat will feature two titans of the industry in Tennessee as they share their strategies for success and the many lessons learned along the way.
CONNECTIONS BREAK SPONSORED BY AVANTOR
1:00 pm
INDUSTRY ADOPTION OF AI
2:00 pm
From medical devices to drug discovery to data that helps delivery of care, artificial intelligence continues to unlock opportunities. This panel will explore real-world examples of AI implementation, overcoming barriers to adoption, regulatory hurdles, and the vision for next steps.
PUTTING THE PATIENT FIRST: RARE DISEASE PATIENT ADVOCACY
3:00 pm
Rare diseases are not as rare as you may think. Currently, there are more than 7,000 known rare diseases in the US that effects roughly 2-6% of the population. The understanding of how to treat rare diseases, early detection efforts, and policy can drastically improve the chances of patients living happy and healthy lives. This panel will discuss what rare disease patients experience to get help and how we can be more mindful in effecting change. Sponsored by Ultragenyx
ECOSYSTEM UPDATE
4:00 pm
VENTURE FORUM
4:15 pm
CLOSING REMARKS & RECEPTION
5:30 pm
The Venture Forum, presented by Holland & Knight, is a unique pitch competition for Tennessee’s emerging life science startups that takes place during Life Science Tennessee’s annual conference, LSTCON. Eligible Tennessee-based startup companies can apply now to compete in this year’s Venture Forum, which will be held on Tuesday, November 19, at the Westin Hotel in downtown Nashville. Attendees will vote on their favorite pitches during the competition to select the “People’s Choice Award” presented by the University of Tennessee’s Research Foundation. We congratulate this year’s finalists:
Auros Pharma
Based in Kingsport, Auros Pharma is a startup pharmaceutical company focused on revolutionizing treatment of respiratory arrest caused by drug overdose, cardiac arrest, and COPD exacerbations. Their approach to drug development is to maximize efficient use of recourses to create novel medications that will still be affordable and therefore accessible to those who need them most.
Corami
Corami is a Memphis-based startup that is revolutionizing heart disease by delivering therapeutics directly to the heart’s outer layers. Corami’s platform taps into a unique space on the heart’s surface—the pericardial cavity—to deliver therapeutics. Using the PerCor™ system, therapeutics embedded in a proprietary controlled-release hydrogel, GelCor™, are placed within the pericardial cavity. This minimally invasive approach can reduce dosing and off-target toxicity— beneficial to any cardiac drug delivery, but essential to the clinical translation of cardiac gene therapy.
Empath Biosciences
Based in Nashville, Empath Biosciences discovers and structurally engineers natural products to generate novel classes of drugs that serve as unique anti-cancer agents. Empath will focus its discovery and development efforts on diseases with high-unmet needs; where current therapies are insufficient or non-existent; and where patients are in desperate need of care. Empath seeks to develop therapies that provide patients with new alternatives to existing care, whether symptomatic relief or curative.
Infusense
Infusense is a Nashville-based startup that developed a biosensor technology for rapid, low-cost, and very accurate drug quantification. Their mission is to revolutionize healthcare by saving millions of lives and billions of dollars with a cutting-edge point-of-care technology, eliminating the need for traditional lab testing to deliver rapid, precise drug quantification.
